FindTrial
Sign In

Self injection Device

Development of Adrenaline Auto injector for patients with serious allergic reactions - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/071117
Enrollment
70
Registered
2024-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

DSTMAHE Hub
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy Volunteers

Exclusion criteria

Exclusion criteria: Sick participants and ICU Subjects

Design outcomes

Primary

MeasureTime frame
validation of the auto-injector deviceTimepoint: at the time of inection, real-time—

Secondary

MeasureTime frame
The low cost indigenized auto-injector for all allergy patients with Anaphylaxis_ in the community and in hospitals too. Early use of adrenaline by the intra-muscular route is lifesavingTimepoint: two years—

Countries

India

Contacts

Public ContactDr Jaidev Mangalore Devdas

National Institute of Technology, Surathkal, Mangalore, Karnataka, India

sharnappaj@nitk.edu.in8884555351

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026